Scholarlink

<p>The present research aims to explore the dosimetric advantages associated with a novel multi-modality radiotherapy platform TaiChiB, which integrates a medical linac and a focused <sup>60</sup>Co γ-ray system. The primary focus of this investigation is to assess the efficacy of this platform in the treatment of prostate cancer. A retrospective study was conducted involving fifteen prostate patients. Each patient had two different treatment plans: a Varian linac x-ray plan (group A), and a TaiChiB plan combined with linac x rays and focused γ rays (group B). In both plan groups, the prescribed dose to the planning target volume (PTV) was 50&#xa0;Gy, with a boost dose of 20&#xa0;Gy to the gross tumor volume (GTV). In the TaiChiB plan, the primary plan was delivered using linac x rays and the boost dose plan was delivered using γ rays. Different criteria were used to evaluate the plan quality and results from the two plan groups were compared through statistical analysis (<i>p</i> &lt; 0.05 as significantly different). All plans from these two groups met the clinical requirements for treatment, and Gamma passing rates were above 95% using the 3%/2&#xa0;mm criterion suggested by TG-218. Regarding the dose coverage to targets, the TaiChiB plan group had a higher mean dose to the GTV (77.46 ± 1.04&#xa0;Gy (B) vs. 71.40 ± 0.33&#xa0;Gy (A), <i>p</i> &lt; 0.01), whereas it maintained a comparable mean dose to the PTV (55.33 ± 1.76&#xa0;Gy (B) vs. 55.23 ± 1.92&#xa0;Gy (A), non-significant). In terms of dose to organs-at-risk (OARs), the TaiChiB plan group showed a lower or comparable mean value. In detail, bladder V<sub>45Gy</sub> (43.90 ± 6.34% (B) vs. 49.83 ± 6.31% (A), <i>p</i> &lt; 0.01); rectum V<sub>45Gy</sub> (38.45 ± 14.38% (B) vs. 51.46 ± 17.18%(A), <i>p</i> &lt; 0.01); intestine V<sub>45Gy</sub> (163.88 ± 18.85 cm<sup>3</sup> (B) vs. 177.18 ± 18.20 cm<sup>3</sup> (A), <i>p</i> &lt; 0.01); left femoral head V<sub>30Gy</sub> (5.63 ± 1.97% (B) vs. 11.83 ± 2.56% (A), <i>p</i> &lt; 0.01); and right femoral head V<sub>30Gy</sub> (4.64 ± 1.94% (B) vs. 10.38 ± 2.73% (A), <i>p</i> &lt; 0.01). The comparison of plan evaluation results showed the superiority of the novel multi-modality radiotherapy platform TaiChiB in dosimetric characteristics by harnessing the physical advantages of γ rays as a supplement to x rays in radiotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the dosimetric advantages of a novel multi-modality radiotherapy platform in prostate cancer

  • 期刊论文

  • 发表日期：

    2025年5月12日

查看全文
  • Jie Duan,
  • Qinghui Yun,
  • Zhongfei Wang,
  • Te Zhang,
  • Xiaohuan Sun,
  • Hua Yang,
  • Weiwei Li,
  • Wei Wang,
  • Hongfei Sun,
  • Liting Chen,
  • Yue Gao,
  • Zhiwei Wei,
  • Zhe Wang,
  • Lina Zhao

摘要

The present research aims to explore the dosimetric advantages associated with a novel multi-modality radiotherapy platform TaiChiB, which integrates a medical linac and a focused 60Co γ-ray system. The primary focus of this investigation is to assess the efficacy of this platform in the treatment of prostate cancer. A retrospective study was conducted involving fifteen prostate patients. Each patient had two different treatment plans: a Varian linac x-ray plan (group A), and a TaiChiB plan combined with linac x rays and focused γ rays (group B). In both plan groups, the prescribed dose to the planning target volume (PTV) was 50 Gy, with a boost dose of 20 Gy to the gross tumor volume (GTV). In the TaiChiB plan, the primary plan was delivered using linac x rays and the boost dose plan was delivered using γ rays. Different criteria were used to evaluate the plan quality and results from the two plan groups were compared through statistical analysis (p < 0.05 as significantly different). All plans from these two groups met the clinical requirements for treatment, and Gamma passing rates were above 95% using the 3%/2 mm criterion suggested by TG-218. Regarding the dose coverage to targets, the TaiChiB plan group had a higher mean dose to the GTV (77.46 ± 1.04 Gy (B) vs. 71.40 ± 0.33 Gy (A), p < 0.01), whereas it maintained a comparable mean dose to the PTV (55.33 ± 1.76 Gy (B) vs. 55.23 ± 1.92 Gy (A), non-significant). In terms of dose to organs-at-risk (OARs), the TaiChiB plan group showed a lower or comparable mean value. In detail, bladder V45Gy (43.90 ± 6.34% (B) vs. 49.83 ± 6.31% (A), p < 0.01); rectum V45Gy (38.45 ± 14.38% (B) vs. 51.46 ± 17.18%(A), p < 0.01); intestine V45Gy (163.88 ± 18.85 cm3 (B) vs. 177.18 ± 18.20 cm3 (A), p < 0.01); left femoral head V30Gy (5.63 ± 1.97% (B) vs. 11.83 ± 2.56% (A), p < 0.01); and right femoral head V30Gy (4.64 ± 1.94% (B) vs. 10.38 ± 2.73% (A), p < 0.01). The comparison of plan evaluation results showed the superiority of the novel multi-modality radiotherapy platform TaiChiB in dosimetric characteristics by harnessing the physical advantages of γ rays as a supplement to x rays in radiotherapy.